SCHEMBL4877330

SCHEMBL4877330

CC(Oc1ccc(Cl)cc1C1CCCCC1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 13/20 1.00
PTGDR Q13258 6/20 1.00
PTGER2 P43116 1/20 0.61
TSHR P16473 1/20 0.58
HTR2A P28223 1/20 0.58
HTR2C P28335 1/20 0.58
HTR2B P41595 1/20 0.58
PPARG P37231 1/20 0.50
PPARD Q03181 1/20 0.50
PPARA Q07869 1/20 0.50
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
ALOX12 P18054 1/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21059480 0.96 PTGDR2 (0.92) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL21059478 0.96 PTGDR2 (0.92) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL21059475 0.93 PTGDR2 (0.87) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL21059473 0.93 PTGDR2 (0.87) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL28437082 0.92 PTGDR2 (0.85) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL28437083 0.92 PTGDR2 (0.85) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL4879185 0.85 PTGDR2 (0.74) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL21059447 0.80 PTGDR2 (0.67) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL21059445 0.80 PTGDR2 (0.67) PTGDR2PTGDRPTGER2TSHRHTR2A
SCHEMBL21059492 0.80 PTGDR2 (0.67) PTGDR2PTGDRTSHRHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269335-A1 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent NOVARTIS AG (CH) 2008-10-30 US disclosed
EP-1756032-A1 CRTH2 RECEPTOR ANTAGONISTS Novartis AG (CH) 2007-02-28 EP disclosed
WO-2005105727-A1 CRTH2 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269335-A1 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent EPX, NR3C2, FPR2 PTGDR2 245/4885PTGDR 151/4885PTGER2 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.